Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
Status: | Active, not recruiting |
---|---|
Conditions: | Cancer, Cancer, Bladder Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - 120 |
Updated: | 12/27/2017 |
Start Date: | November 2009 |
End Date: | October 2023 |
A Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized
radiation therapy that delivers a high dose of radiation directly to the tumor may kill more
tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as
cisplatin, mitomycin C, and fluorouracil, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving radiation
therapy together with cisplatin may kill more tumor cells.
PURPOSE: This phase II trial is studying how well radiation therapy given together with
chemotherapy works in treating patients with stage I bladder cancer.
radiation therapy that delivers a high dose of radiation directly to the tumor may kill more
tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as
cisplatin, mitomycin C, and fluorouracil, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving radiation
therapy together with cisplatin may kill more tumor cells.
PURPOSE: This phase II trial is studying how well radiation therapy given together with
chemotherapy works in treating patients with stage I bladder cancer.
OBJECTIVES:
Primary
- To evaluate the rate of freedom from radical cystectomy at 3 years.
Secondary
- To evaluate the rate of freedom from radical cystectomy at 5 years.
- To evaluate the rate of freedom from the development of distant disease progression at 3
and 5 years.
- To evaluate the rate of freedom from progression of bladder tumor to stage T2 or greater
at 3 and 5 years.
- To evaluate disease-specific survival and overall survival.
- To evaluate the incidence of acute and late pelvic toxicity.
- To evaluate the efficacy of this treatment approach in preventing the recurrence of any
local bladder tumor.
- To evaluate the potential value of tumor histopathology plus molecular genetic, DNA
content, and urine proteomics parameters as possible significant prognostic factors for
tumor control with this treatment approach.
- To collect American Urological Association symptom scores at baseline and at 3 years.
OUTLINE: Beginning within 10 weeks of transurethral resection of the bladder tumor, patients
undergo 3-dimensional conformal radiotherapy once daily 5 days per week during weeks 1-7 (34
fractions). Patients also receive 1 of 2 radiosensitizing chemotherapy regimens concurrently
with radiotherapy.
- Regimen I: Patients receive cisplatin IV on days 1-3 of weeks 1, 3, and 5.
- Regimen II: Patients receive mitomycin C IV on day 1 of radiotherapy and fluorouracil IV
continuously over days 1-5 of weeks 1 and 4.
Patients with a persistent tumor on re-evaluation may undergo radical cystectomy.
Tissue, blood, and urine samples may be collected periodically for biomarker and other
analysis.
After completion of study treatment, patients are followed up every 3 months for 1 year,
every 4 months for 1 year, every 6 months for 3 years, and annually thereafter.
Primary
- To evaluate the rate of freedom from radical cystectomy at 3 years.
Secondary
- To evaluate the rate of freedom from radical cystectomy at 5 years.
- To evaluate the rate of freedom from the development of distant disease progression at 3
and 5 years.
- To evaluate the rate of freedom from progression of bladder tumor to stage T2 or greater
at 3 and 5 years.
- To evaluate disease-specific survival and overall survival.
- To evaluate the incidence of acute and late pelvic toxicity.
- To evaluate the efficacy of this treatment approach in preventing the recurrence of any
local bladder tumor.
- To evaluate the potential value of tumor histopathology plus molecular genetic, DNA
content, and urine proteomics parameters as possible significant prognostic factors for
tumor control with this treatment approach.
- To collect American Urological Association symptom scores at baseline and at 3 years.
OUTLINE: Beginning within 10 weeks of transurethral resection of the bladder tumor, patients
undergo 3-dimensional conformal radiotherapy once daily 5 days per week during weeks 1-7 (34
fractions). Patients also receive 1 of 2 radiosensitizing chemotherapy regimens concurrently
with radiotherapy.
- Regimen I: Patients receive cisplatin IV on days 1-3 of weeks 1, 3, and 5.
- Regimen II: Patients receive mitomycin C IV on day 1 of radiotherapy and fluorouracil IV
continuously over days 1-5 of weeks 1 and 4.
Patients with a persistent tumor on re-evaluation may undergo radical cystectomy.
Tissue, blood, and urine samples may be collected periodically for biomarker and other
analysis.
After completion of study treatment, patients are followed up every 3 months for 1 year,
every 4 months for 1 year, every 6 months for 3 years, and annually thereafter.
DISEASE CHARACTERISTICS:
- Pathologically (histologically or cytologically) diagnosis of carcinoma of the bladder
within 105 days prior to registration.
- Patients with operable tumors that are primary high grade urothelial carcinoma of
the bladder exhibiting histologic evidence of invasion into the lamina propria
(disease clinical stage T1) or a high grade stage Ta urothelial carcinoma without
hydronephrosis.
- Patients with disease involvement of the prostatic urethra with urothelial
carcinoma and have no evidence of stromal invasion of the prostate. If the
patient's initial tumor was a high grade Ta urothelial carcinoma then his/her
recurrent tumor must be a high grade stage T1 urothelial carcinoma to be
eligible.
- Patients must have a high grade urothelial carcinoma stage Ta or T1 that has
recurred within 540 days after completion of the initial treatment (transurethral
resection bladder tumor [TURBT] and intravesical bacillus Calmette-Guerin [BCG]
immunotherapy) or have presented to a participating urologist who judged BCG
therapy is contraindicated because this patient may be immuno-compromised or
because the patients refuses BCG therapy
- No confirmed tumor-related hydronephrosis
- No pN+ or > T1 disease
- No histologically or cytologically confirmed node metastases
- If radiologic evaluation of a lymph node is interpreted as "positive", this must
be evaluated further either by lymphadenectomy or by percutaneous needle biopsy
- No evidence of distant metastases
- Patients for whom radical cystectomy is the standard next therapy per urologic
guidelines, in the judgement of the participating urologist, are eligible
- Must have an adequately functioning bladder as judged by the participating urologist
and radiation oncologist and have undergone a visibly complete re-staging TURBT by the
participating urologist that shows (or is present on the outside pathology specimen) a
T1G2 or T1G3 tumor with uninvolved muscularis propria in the specimen and, if on
prostatic urethral biopsy mucosal carcinoma is present, there is no evidence on biopsy
in the prostatic stroma of tumor invasion
PATIENT CHARACTERISTICS:
- Zubrod performance status 0-1
- White blood cell count (WBC) ≥ 4,000/mm^3
- Absolute neutrophil count (ANC) ≥ 1,800/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 10.0 g/dL (transfusion or other intervention allowed)
- Serum creatinine ≤ 1.5 mg/dL
- Serum bilirubin ≤ 2.0 mg/dL
- Glomerular filtration rate (GFR) > 25 mL/min (for patients receiving cisplatin, GFR >
60 mL/min)
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception
- Able to tolerate systemic chemotherapy combined with radiotherapy and a radical
cystectomy (if necessary), in the opinions of the urologist, radiation oncologist, and
medical oncologist
- No prior or concurrent malignancy of any other site or histology (except for
nonmelanomatous skin cancer, T1a prostate cancer, or carcinoma in situ of the uterine
cervix) unless the patient has been disease-free for ≥ 5 years
- No severe, active co-morbidity including any of the following:
- Unstable angina and/or congestive heart failure that required hospitalization
within the past 6 months
- Transmural myocardial infarction that occurred within the past 6 months
- Acute bacterial or fungal infection requiring IV antibiotics at the time of
registration
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness
requiring hospitalization or precluding any study therapy at the time of
registration
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
- AIDS based upon the current Centers for Disease Control definition (HIV testing
not required)
- No prior allergic reaction to cisplatin, mitomycin, or 5-fluorouracil
PRIOR CONCURRENT THERAPY:
- No prior systemic chemotherapy for bladder cancer
- Prior chemotherapy for a different cancer allowed
- No prior radiotherapy to the region of this cancer that would result in overlap of
radiotherapy fields
- No concurrent drugs that have potential nephrotoxicity or ototoxicity (e.g.,
aminoglycoside)
We found this trial at
13
sites
Fall River, Massachusetts 02721
Phone: 508-674-5600
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
Galveston, Texas 77555
(409) 772-1011
Phone: 409-772-1950
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
Click here to add this to my saved trials
One Medical Center Drive
Lebanon, New Hampshire 03756
Lebanon, New Hampshire 03756
(603) 653-9000
Phone: 603-650-7609
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center Norris Cotton Cancer Center at DHMC in...
Click here to add this to my saved trials
161 North Forge Street
Akron, Ohio 44304
Akron, Ohio 44304
(330) 375-7280
Phone: 330-375-6101
Summa Center for Cancer Care at Akron City Hospital Summa Health System is a leader...
Click here to add this to my saved trials
Click here to add this to my saved trials
1365 Clifton Rd NE
Atlanta, Georgia 30322
Atlanta, Georgia 30322
(404) 778-1900
Phone: 404-778-1900
Winship Cancer Institute at Emory University Winship Cancer Institute of Emory University is Georgia
Click here to add this to my saved trials
900 Caton Ave.
Baltimore, Maryland 21229
Baltimore, Maryland 21229
410-368-6000
Phone: 410-368-2965
St. Agnes Hospital Cancer Center Saint Agnes Hospital is leading Maryland in the battle against...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials